# Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease

> **NCT00770601** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 7 (actual)

## Conditions studied

- NOMID
- CINCA Syndrome

## Interventions

- **DRUG:** Canakinumab

## Key facts

- **NCT ID:** NCT00770601
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01-26
- **Primary completion:** 2011-02-17
- **Final completion:** 2011-02-17
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2021-06-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00770601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00770601, "Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00770601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*